Рет қаралды 483
Dr. Mark Benson describes advances in technology that are identifying new pharmacological targets in preventive cardiology. He covers how genomics has identified several emerging classes of CV medications that are currently in Phase 1-3 trials. Dr. Benson also discusses the promise for future therapeutic target discovery in preventive cardiology.